Suppr超能文献

基于BATMAN-TCM探讨西黄丸调节免疫功能治疗乳腺导管上皮不典型增生的分子机制。 (注:原文中“Breast Precancerous Lesions”准确的医学术语应该是“乳腺导管上皮不典型增生”,更符合医学语境表述,这里按照准确术语给出译文,若严格按原文翻译则为“乳腺癌前病变” )

Based on BATMAN-TCM to Explore the Molecular Mechanism of Xihuang Pill Regulating Immune Function to Treat Breast Precancerous Lesions.

作者信息

Li Dehui, Fan Huanfang, Dong Jingfei, Sun Chunxia, Su Yifan, Liu Jiao, Gu Yiting

机构信息

Hebei Province Hospital of Chinese Medicine;The First Affiliated Hospital of Hebei University of Chinese Medicine, Shi Jiazhuang, 050011, People's Republic of China.

出版信息

Breast Cancer (Dove Med Press). 2021 Dec 23;13:725-742. doi: 10.2147/BCTT.S339607. eCollection 2021.

Abstract

OBJECTIVE

The specific mechanism of Xihuang Pill in the treatment of breast precancerous lesions and breast cancer has not yet been elucidated.

METHODS

In our study, BATMAN-TCM (a Bioinformatics Analysis Tool for Molecular mechanisms of Traditional Chinese Medicine) was used to forecast the relationship among chemical components, immune targets, and diseases of each herb in Xihuang Pill and constructed a component-target-disease network. Taking breast precancerous lesion model rats as the research object, the molecular mechanism of Xihuang Pill regulating immunity was analyzed.

RESULTS

BATMAN-TCM prediction showed that 309 genes were enriched in the biological process of "immune system response", which was the target of Xihuang Pill to regulate the immune system. The target of breast cancer disease and the genes related to Xihuang Pill's immune system response were crossed, and 88 cross genes were obtained. According to the enrichment results of GO/KEGG pathway, T cell activation was found to be the most relevant. We select Th1 cells (IL-2, IFN-γ) and Th2 cells (IL-4, IL-10) among them for animal experiment verification. The results show that Xihuang Pill can upregulate the serum IFN-γ and IL-2 levels, reduce the IL-4 and IL-10 levels, and regulate the balance of Th1/Th2 cells in the peripheral blood of rats with breast precancerous lesions.

CONCLUSION

Xihuang Pill targets a variety of immune-related molecules related to breast precancerous lesions and is a traditional Chinese medicine formula that effectively regulates immune function.

摘要

目的

西黄丸治疗乳腺增生性病变及乳腺癌的具体机制尚未阐明。

方法

本研究利用中药分子机制生物信息分析工具(BATMAN-TCM)预测西黄丸中各味中药的化学成分、免疫靶点与疾病之间的关系,构建成分-靶点-疾病网络。以乳腺增生性病变模型大鼠为研究对象,分析西黄丸调节免疫的分子机制。

结果

BATMAN-TCM预测显示,309个基因富集于“免疫系统反应”生物学过程,此为西黄丸调节免疫系统的作用靶点。将乳腺癌疾病靶点与西黄丸免疫系统反应相关基因进行交叉分析,得到88个交叉基因。根据GO/KEGG通路富集结果,发现T细胞活化最为相关。从中选取Th1细胞(IL-2、IFN-γ)和Th2细胞(IL-4、IL-10)进行动物实验验证。结果显示,西黄丸可上调乳腺增生性病变大鼠外周血中IFN-γ和IL-2水平,降低IL-4和IL-10水平,调节Th1/Th2细胞平衡。

结论

西黄丸作用于多种与乳腺增生性病变相关的免疫相关分子,是一种有效调节免疫功能的中药复方。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b86b/8711846/fe709aa42cb8/BCTT-13-725-g0002.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验